Coluracetam

Coluracetam is a synthetic nootropic of the racetam family, sharing the characteristic 2-pyrrolidinone core of that class while carrying a distinctive tetrahydrofuro-quinoline structure. It was first synthesized under the code MKC-231 by the Japanese pharmaceutical company Mitsubishi Tanabe Pharma, which investigated it as a treatment for the cognitive decline of Alzheimer's disease ^[1][2]. The rights were later acquired by BrainCells Inc, which coded it BCI-540 and explored it in early clinical work for major depressive disorder and comorbid anxiety, after which it entered the wider nootropic community as a research compound.

Unlike most racetams, coluracetam is defined pharmacologically as a high-affinity choline uptake (HACU) enhancer. High-affinity choline uptake is the rate-limiting step in the manufacture of the neurotransmitter acetylcholine, so a molecule that accelerates it can, in principle, raise cholinergic tone ^[3]. Much of the foundational research used AF64A, a cholinotoxin that damages cholinergic neurons to model the deficits seen in Alzheimer's disease; in these animals coluracetam reversed choline uptake deficits and rescued learning in water-maze tasks ^[1][2]. Additional studies documented neuroprotective effects against glutamate excitotoxicity and benefits in a phencyclidine model of schizophrenia-like cognitive impairment ^[4][5].

Coluracetam is not an approved drug in any major jurisdiction and is not classified as a dietary supplement; it is sold and used as a research chemical, typically as a powder or in a stabilized solution, and is frequently grouped with the cholinergic nootropics. Its unusual persistence is notable: procognitive effects have been observed to remain well after the compound is no longer detectable in the brain, suggesting a durable change in the regulation of the choline transporter itself ^[1].

NO HUMAN SAFETY DATA HAS EVER BEEN PUBLISHED. NCT00621270 enrolled 115 people and completed in October 2009 with adverse events, laboratory values, ECGs, vital signs and a Physician Withdrawal Checklist all listed as secondary outcomes; none of it was ever posted or published. The adverse-effect profile of this compound in humans is therefore genuinely unknown, not merely benign-looking. Secondary reporting on the earlier Mitsubishi Alzheimer's programme states the drug met safety expectations but missed efficacy endpoints; that is a company characterisation, not a published dataset.

WHAT THE PROTOCOL REVEALS. The registered Phase 2a exclusion criteria are informative about what the sponsor was monitoring. The trial excluded anyone with a history of seizures; anyone with known hypersensitivity to cholinesterase inhibitors or cholinergic agonist drugs; and, notably, anyone with low red blood cell, haemoglobin, white blood cell, platelet or reticulocyte counts, or current macrocytosis, and it barred concomitant drugs known to be related to agranulocytosis or aplastic anaemia. That combination points to a haematological safety question the sponsor was actively guarding against. No published finding confirms an actual haematological signal, so this should be reported as a monitoring concern inferred from the protocol, not as an established adverse effect.

PRECLINICAL. At behaviourally effective oral doses in rats, coluracetam did not produce the tremor, salivation or hypothermia seen with high-dose tacrine (PMID 8740080). Intracerebroventricular administration in rats caused only mild centrally mediated hyperglycaemia, described as pharmacologically negligible compared with neostigmine (PMID 10082325). No published rodent or non-rodent chronic toxicology, reproductive toxicology or genotoxicity data was found.

INTERACTIONS. None have been studied in humans. Additive cholinergic effects alongside cholinesterase inhibitors (donepezil, rivastigmine, galantamine, huperzine A) or direct cholinergic agonists are mechanistically plausible and were treated as a contraindication in the trial design, but are untested. No CYP inhibition or induction data was found.

REGULATORY. Not approved for any indication in any country. NCATS Inxight (UNII V6FL6O5GR7) lists it as investigational with development discontinued, having failed to reach endpoints in Alzheimer's trials and with the Phase 2 depression and anxiety programme halted. ChEMBL records max_phase 2 with no approval. It is not a lawful dietary supplement ingredient in the United States, since FDA's stated position is that racetams do not meet the statutory definition of a dietary ingredient and are unapproved new drugs. Be precise on one point: FDA's February 2019 warning letters to nootropics vendors named adrafinil, aniracetam, noopept, oxiracetam, phenibut, phenylpiracetam, piracetam and pramiracetam, and did NOT name coluracetam specifically. It is not scheduled under the US Controlled Substances Act.

ANTI-DOPING. Coluracetam is not named anywhere on the WADA 2026 Prohibited List; this was verified by downloading and text-searching the published list PDF effective 1 January 2026, where the term returns zero matches and the only racetam present is fonturacetam (4-phenylpiracetam, carphedon) under S6 Stimulants. It is nonetheless a real anti-doping risk on two independent grounds. First, category S0 prohibits at all times "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", explicitly naming drugs under clinical development or discontinued; coluracetam matches that description exactly. Second, a 2025 review co-authored by the Polish Anti-Doping Agency and a WADA-affiliated anti-doping science centre classifies Coluracetam (BCI-540; MKC-231) under "unclear status, presumed to meet WADA criteria" by similarity to 4-phenylpiracetam (PMID 41048238). Tested athletes should treat coluracetam as prohibited.

Coluracetam was originally developed under the code name MKC-231 by the Japanese pharmaceutical company Mitsubishi Tanabe Pharma, which investigated it in the 1990s as a candidate treatment for the cognitive decline of Alzheimer's disease. Early studies focused on its unusual ability to enhance high-affinity choline uptake and to restore learning and memory in animals whose cholinergic neurons had been chemically damaged, work reported by Japanese pharmacologists such as Murai and colleagues in 1994.

Rights to the molecule were later acquired by the American company BrainCells Inc., which explored it for major depressive disorder; a Phase 2a trial examined coluracetam in patients with depression and comorbid anxiety who had not responded to prior therapy. Although it did not advance to approval as a prescription drug, coluracetam subsequently entered the nootropic community, where it is sold and used as a research chemical and dietary supplement. Its documented history is comparatively short and centers on these industry programs, so much of what is claimed for it in everyday use rests on the original preclinical pharmacology rather than large human trials.

Among racetams, coluracetam has earned a following for its unusual and elegant mechanism: rather than simply nudging existing receptors, it appears to increase the cell's capacity to take up choline, the raw material for acetylcholine. Users often describe sharper focus, enhanced working memory, and, intriguingly, subtle changes in visual perception such as brighter or more vivid color. It is frequently paired conceptually with a choline source, since the transporter it enhances depends on an adequate supply of substrate.

Enthusiasts also point to its clinical pedigree in depression research as a sign of a broader mood dimension to its effects. Honesty requires noting that robust human efficacy data are limited and that much of its appeal derives from compelling animal studies and self-reported experience, so it is best regarded as a promising and well-tolerated nootropic rather than a proven cognitive medicine.